Skip Navigation



JAC Advance Access published online on July 1, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg318
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/2/303    most recent
dkg318v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scrascia, M.
Right arrow Articles by Pazzani, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scrascia, M.
Right arrow Articles by Pazzani, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas

Maria Scrascia 1 , Maria Forcillo 1 , Francesco Maimone 2 , and Carlo Pazzani 2 *

1 Dipartimento di Anatomia Patologica e di Genetica, Sezione di Genetica, Università di Bari, Via G. Amendola 165/A, 70126 Bari
2 Dipartimento di Anatomia Patologica e di Genetica, Sezione di Genetica, Università di Bari, Via G. Amendola 165/A, 70126 Bari; Interuniversity Research Centre for Sustainable Development, Università di Roma ‘La Sapienza', Rome, Italy

* Corresponding author. E-mail: pazzani{at}biologia.uniba.it..

Received 18 February 2003 ; revised 29 April 2003 ; accepted 6 May 2003

Abstract

Four hundred and eight clinical strains of Vibrio cholerae isolated from different geographical areas and with different antimicrobial resistance patterns were tested for susceptibility to rifaxim-in, a non-absorbable antibiotic active in vitro against Gram-negative bacteria. The MICs ranged from 0.5 to 4 mg/L for all strains. These values and the pharmacokinetic properties suggest rifaximin as an attractive antimicrobial agent for cholera.

Keywords: rifamycin derivative, antimicrobial activity, cholera
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
M. Scrascia, F. Maimone, K. A. Mohamud, S. F. Materu, F. Grimont, P. A. D. Grimont, and C. Pazzani
Clonal Relationship among Vibrio cholerae O1 El Tor Strains Causing the Largest Cholera Epidemic in Kenya in the Late 1990s.
J. Clin. Microbiol., September 1, 2006; 44(9): 3401 - 3404.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.